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Abstract
Trichosporon is a yeast-like basidiomycete, a conditional pathogenic fungus that is rare in the
clinic but often causes fatal infections in immunocompromised individuals. Trichosporon asahii is the most common pathogenic fungus in this genus and the occurrence of infections has
dramatically increased in recent years. Here, we report a systematic literature review detailing
140 cases of T. asahii infection reported during the past 23 years. Statistical analysis shows that
T. asahii infections were most frequently reported within immunodeficient or immunocompromised patients commonly with blood diseases. Antibiotic use, invasive medical equipment
and chemotherapy were the leading risk factors for acquiring infection. In vitro susceptibility,
clinical information and prognosis analysis showed that voriconazole is the primary drug of
choice in the treatment of T. asahii infection. Combination treatment with voriconazole and
amphotericin B did not show superiority over either drug alone. Finally, we found that the
types of infections prevalent in China are significantly different from those in other countries.
These results provide detailed information and relevant clinical treatment strategies for the
diagnosis and treatment of T. asahii infection.

Introduction

© The Author(s), 2020. Published by
Cambridge University Press. This is an Open
Access article, distributed under the terms of
the Creative Commons Attribution licence
(http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted re-use,
distribution, and reproduction in any medium,
provided the original work is properly cited.

Over the past 30 years, the incidence of fungal infection has increased dramatically in patients
with cancer, deep burns, organ transplants and those under treatment with hormones and
immunosuppressive agents, becoming one of the main causes of death in these individuals.
In addition to common fungal infections such as candidiasis and aspergillosis, infections
caused by non-candida yeast such as trichosporonosis are increasing in immunosuppressed,
immunocompromised and immunodeficient individuals with severe conditions and high mortality rates [1–4]. Trichosporon is a yeast-like basidiomycete. It is ubiquitous in nature meaning it is present in soil, water, plants, mammals, birds, etc. and is also present among the
human body’s natural flora; however, it can become pathogenic to the humans in certain
cases [5–8]. Hermann Beigel first proposed the concept of Trichosporon in 1865 and observed
that it can cause hair infection. The classification and naming of Trichosporon has then changed multiple times over the years. Initially, all Trichosporon spp. were classified as Trichosporon
beigelii, and it was thought that the strain mainly causes infection in superficial hair, and rarely
causes deep-seated infection [6]. However, subsequent research showed that T. beigelii has
great morphologic variation, as well as physiological and biochemical variance [9]. In 1992,
Gueho et al. revised the taxonomy of 20 species of Trichosporon, including six pathogens:
Trichosporon asahii, T. asteroides, T. cutaneum, T. inkin, T. mucoides and T. ovoides [6, 10–12].
In 1994 and 1995, Sugita et al. reviewed the genus Trichosporon and proposed a new classification
that included 17 different species of Trichosporon and five varieties [13]. By 2002, the number of
Trichosporon species had increased to 25, of which eight were associated with human infections,
including two new species, T. domesticum and T. montevideense [14]. Presently, 50 Trichosporon
species are recognised, of which 16 are known to be pathogenic [15–19].
Current research indicates that risk factors for Trichosporon infection include neutropaenia
(an abnormally low amount of neutrophils), organ transplantation, diabetes, end-stage renal
disease, HIV infection and use of immunosuppressive agents and invasive medical equipment
[5, 6, 20–27]. Trichosporonosis is associated with a variety of infection types, including superficial skin and hair infections, summer-type hypersensitivity pneumonitis (SHP), chronic
pneumonia, meningitis, endocarditis, disseminated infections and fungaemia [28–41].
Trichosporon infections are also often misdiagnosed as other types of fungal infections
[42], and have proven difficult to treat. Before 2000, physicians recommended amphotericin
B for treatment of Trichosporon infections; however, usage of this drug has been reported
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to be ineffective [43]. The combination of amphotericin B and
flucytosine was also suggested for treatment [37, 44, 45], but no
studies are published that compare effectiveness between combined and individual antifungal drug treatment. When azole
pharmaceuticals appeared on the market (especially voriconazole), most in vitro susceptibility testing showed that they were
superior to amphotericin B for treating trichosporosis [46–48];
however, the in vitro effects of antifungal drugs are not fully representative of their therapeutic effectiveness in humans. The
guidelines developed by ESCMID/ECMM in 2014 recommend
voriconazole for the treatment of trichosporosis, although it is
noted that the development of this guide relies mainly on in
vitro susceptibility testing results, animal model test results and
a few case reports [49].
Almost all cases of Trichosporon infection reported before 1994
were named T. beigelii. In contrast, isolates of Trichosporon spp.
reported in the past 20 years are of various types, and numerous
species of Trichosporon are known to exhibit different pathogenic
characteristics. For example, T. asteroids and T. cutaneum are the
main pathogenic species known to cause superficial skin infections
[6]. On the other hand, T. asahii is the most prominent clinical
pathogen in the genus. T. asahii causes more than half of the infections of the genus [50], and the mortality caused by deep invasive
infections is greater than 70%. In 1992, Gueho et al. [6] proposed
another classification of Trichosporon spp., and confirmed that T.
asahii was the main pathogen causing deep trichosporosis.
The incidence of T. asahii infection has increased significantly in
the past 20 years [1, 3]. It is commonly found in immunodeficient
and immunocompromised patients, and individuals with blood diseases [23, 51, 52]. A few studies also reported T. asahii infection in
healthy individuals [21, 22]. In addition, different species of
Trichosporon possess different drug sensitivities. For example,
amphotericin B has a higher minimum inhibitory concentration
(MIC) against T. asahii, T. faecale and T. coremiiforme, while T.
inkin, T. ovoides, T. japonicum, T. domesticum, T. montevideense
and T. cutaneum have lower MICs [46, 53–56]. Therefore, it is
important to accurately analyse the epidemiological characteristics
of different species of Trichosporon so the susceptibility and risk factors of infection can be obtained. This information can then enhance
patient diagnosis, treatment, medication and outcome prediction.
Accurate epidemiological analysis of Trichosporon infections,
especially T. asahii, can highlight susceptibility to infection and
improve patient diagnosis, treatment and prognosis. Although
there is some literature reviewing Trichosporon disease [57–59],
a comprehensive analysis of epidemiological characteristics, clinical treatment and prognosis of T. asahii infection has not been
published. Here we systematically analysed the epidemiological
characteristics, risk factors, clinical manifestations, diagnosis,
treatment, medication and prognosis of T. asahii infections
reported in the English literature from 1996 to 2019 and in
Chinese literature from 2009 to 2019. We then compared the
infections in China with those in other countries to determine significant differences in divergent clinical categories.

Materials and methods
Literature collection
In order to do a comprehensive analysis of clinical studies regarding T. asahii infections, we performed a systematic literature
review to identify original cases in both English and Chinese literature. First, we reviewed all references from the PubMed
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database by using the keywords T. asahii, trichosporon asahii
and trichosporonosis. The search was then limited to studies
including human subjects, clinical trials and case reports. A
search was also conducted on the Chinese medical database
WANFANG (http://www.wanfangdata.com.cn/index.html). To
standardise analysis, the following patient information was examined for each case: time of onset, study area, demographic data,
possible pathogenesis, type of underlying disease, source of specimen, identification method of strain, type and location of infection, treatment and outcome. Published studies with missing
case information from any of these categories were excluded.
All literature reviewed was published between 1996 and 2019.
Statistical analysis of epidemiological data
For each category, the distribution of data was analysed by using a
descriptive statistical analysis. To understand the different causal
factors and therapy results between 51 Chinese cases and 89 cases
from other countries, we compared each cohort with respect to
the patient information. A Fisher’s exact test was used to compare
the effectiveness of the three antifungal drug groups (amphotericin B; triazoles; amphotericin B plus triazoles), where P < 0.05 was
considered statistically significant.
Results
Patient population
Systematic literature review yielded a total of 140 cases of T. asahii
infection, including 51 cases in Chinese literature and 89 in
English literature reported from 1996 to 2019. These cases were
distributed throughout Asia, Europe, North and South America
and Africa, in which Asia had the largest proportion (108/140,
77.1%). Cases reported from China, Japan and India represented
65.7% of the total. Among other countries and regions, 10 cases
were reported from the United States (Fig. 1a). The number of
cases in Asia dramatically increased from 2006 to 2015, but
only 16 cases were observed in other years (Fig. 1b).
Of the 140 patients with T. asahii infection, 83 were male (83/
140, 59.3%), 47 were female (47/140, 33.6%) and the gender of
remaining 10 patients was not reported (eight were newborn premature infants), achieving a ∼1.77-fold ratio of males to females.
The age of onset ranged from 0 to 92 years old, where the group
of individuals over 65 years old represented the largest proportion
(48/140, 34.3%). For cases from Asia, the older individual groups
have higher proportions of T. asahii infection, which is also consistent with observations from Europe and the Americas (Fig. 1c).
Risk factors for T. asahii infection
Previous studies found divergent risk factors related to trichosporosis including antibiotic usage, invasive medical equipment,
intensive care unit (ICU) hospitalisation and others [60, 61].
Among the 140 patients with T. asahii infection, we also found
that antibiotic and invasive medical equipment users were the
two major groups with proportions of 46.4% (65/140) and
44.3% (62/140), respectively (Fig. 2a). Overall, the use of broadspectrum antibiotics, the use of invasive medical devices, neutropaenia and ICU hospitalisation remain the four greatest risk
factors for T. asahii infection. Our results proved to be consistent
with previous studies. For example, Kontoyannis et al. [61] analysed 17 patients with trichosporosis and a history of oncology
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Fig. 1. Basic statistical features of 140 cases of T. asahii infection. (a) Regional distribution. (b) Temporal distribution of 140 cases (year). (c) Age distribution.

and found that 12 patients used central venous catheters and 11
patients had neutropaenia. Ruan et al. [60] analysed 19 patients
with disseminated trichosporosis infections in Taiwan between
2000 and 2008, and found that 18 patients used central venous
catheters and 17 patients used broad spectrum antibiotics.
We further checked if prior antifungal treatment/prophylaxis
is a risk factor for T. asahii infection. Based on the previous definitions of breakthrough invasive fungal infection (IFI) [62], a total
of 22 cases can be classified as breakthrough IFI during prophylaxis or empiric treatment (Table 1). Among them, amphotericin
B (27.3%), echinocandin (22.7%) and fluconazole (13.6%) are
three top used antifungal drugs with regard to risk for breakthrough IFI. Furthermore, IFI was also observed after prophylactic
use of antifungal drugs in combination, e.g. fluconazole plus
amphotericin B (9.1%). After targeted antifungal treatment of T.
asahii infection, nine patients were cured but 13 died.

Underlying disease types
Haematologic diseases (39/140, 27.9%), diabetes (19/140, 13.6%)
and pulmonary diseases (17/140, 12.1%) were the three most
common pre-existing illnesses in patients within the 140 T. asahii
infection cases. Among the patients with blood diseases, 28
patients had leukaemia, accounting for 71.8%. There were also
patients with other maladies and conditions such as AIDS,
organ transplants and various cancers. Interestingly, five patients
were apparently healthy prior to infection without any preexisting illnesses (Table 2). The distribution of underlying

diseases among T. asahii infections differs from the distribution
observed among general Trichosporon infections. In a study of
underlying diseases in patients with Trichosporon infection,
Girmenia et al. [57] reported that the three most common preexisting clinical conditions were haematological diseases, peritoneal dialysis and malignant tumours. Our study also showed that in
patients with T. asahii infection, blood diseases (mainly blood
cancer and neutropaenia) are most common, diabetes is second
and lung disease follows as third.
Clinical manifestations, type of infection and site of infection
The clinical manifestations of T. asahii infected patients were
non-specific, but varied with different infection sites and types
of infections. The major types of infections were urinary tract
infection (35/140, 25%), fungaemia (33/140, 23.6%) and disseminated infection (20/140, 15.7%). A few other infections reported
were SHP, peritonitis, infections found superficially on the skin
and in hair, along with various other infection types (Table 3).
Among the 140 patients with T. asahii infections, infection of
the blood was the most common (47/140, 33.6%), followed by
the urinary system (40/140, 28.6%), respiratory system (29/140,
20.7%) and integumentary system (21/140, 15.0%) (Fig. 2b).
Strain identification methods
T. asahii was isolated from a variety of clinical specimens. Of the
140 patients studied, 47 were diagnosed using a specimen
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Fig. 2. Proportions of 140 cases on risk factors (a), infected tissues (b), test samples (c) and testing methods (d).

Table 1. Statistical summary of 22 breakthrough IFI with prior antifungal
treatment/prophylaxis
Prophylactic antifungal
drugs

No.（%）

Echinocandin

5 (22.7)

24383917, 23419599,
25328390, 17882360

Amphotericin B

6 (27.3）

26351595, 18362402,
12087540, 16964817,
16217998

Fluconazole

3 (13.6)

22370746, 20436525,
11337182

Itraconazole

2 (9.1)

17322000, 16838224

Posaconazole

1 (4.6)

17690928

Fluconazole + micafungin

1 (4.6)

15231763

Fluconazole +
amphotericin B

2 (9.1）

25383317, 11477533

Fluconazole +
itraconazole +
amphotericin B

1 (4.6）

23970618

Unknown

1 (4.6)

18356615

Table 2. The underlying disease types of 140 patientsa with T. asahii infection

Citations (PMID)

a

obtained from blood (33.6%), 39 were diagnosed from a urine
specimen (27.9%) and 27 were diagnosed from a sputum specimen (19.3%). A complete description of samples used for testing
can be found in Figure 2c. Of the 140 T. asahii cases, 135 cases

Types of
underlying
disease

No.（%）

Types of underlying
disease

Blood disease

39 (27.9)

Malignant tumour

Diabetes

19 (13.6）

Fracture

4 (2.9)

Lung disease

17 (12.1)

AIDS

3 (2.1)

Other

14 (10)

Organ
transplantation

3 (2.1)

Premature infants

10 (7.1)

Chronic gastritis

3 (2.1）

After surgery

7 (5)

Hypothyroidism

2 (1.4)

Chronic renal
insufficiency

6 (4.3)

Rheumatoid
arthritis

2 (1.4)

Summer allergic
pneumonia

4 (2.9)

Diabetic
nephropathy

1 (0.7)

No.（%）
4 (2.9)

Some patients have more than one underlying disease.

(96.4%) described the method for identifying T. asahii.
Morphological methods combined with biochemical methods
were used most commonly (96/135, 71.1%). The antigen inhalation test was the identification method used for the five patients
with SHP (Fig. 2d). Among the 135 cases, 128 patients (128/135
94.8%) were tested by using morphological methods (API 20C
AUX yeast identification system, ID 32C yeast identification
system, Vitek automatic microbial identification system).
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Table 3. Clinical illnesses in patients with T. asahii infection
Type of infection

No.（%）

Type of infection

No.（%）

Urinary infection

35 (25)

Glossitis

1 (0.7)

Fungaemia

33 (23.6)

Conjunctivitis

1 (0.7)

Disseminated infection

20 (15.7)

Discitis

1 (0.7)

Lung infection

15 (10.7)

Infective endocarditis

1 (0.7)

Skin infections

8 (5.7)

Black hairy knot disease

1 (0.7)

Chronic pneumonia

7 (5)

Lymphadenitis

1 (0.7)

Other

4 (2.9)

Endophthalmitis

1 (0.7)

Peritonitis

3 (2.1)

Brain abscess

1 (0.7)

Meningoencephalitis

2 (1.4)

Synovitis

1 (0.7)

Esophagitis

2 (1.4)

Summer allergic pneumonia

1 (0.7)

Table 4. Drug effectiveness by in vitro drug sensitivity test in 140 patientsa with
T. asahii infection

Drug

2006–2019

No. (%）

No. (%）

Amphotericin B

1 (10)

24 (21.8)

Voriconazole

4 (40)

41 (37.3)

Itraconazole

3 (30)

19 (17.3)

Miconazole

0 (0)

1 (0.9)

Ketoconazole

1 (10)

0 (0)

Fluconazole

1 (10)

Total
a

1996–2005

10 (100.0)

25 (22.7)
110 (100.0)

Some patients were sensitive to more than one drug.

Biochemical techniques were used in 119 cases (119/135, 88.1%)
and 24 cases (24/135, 18.4%) used a genetic method (LSU, D1/
D2, ITS region nucleic acid sequence determination).
In vitro susceptibility test
Of the 140 patients with T. asahii infection, 91 had an in vitro susceptibility test, consisting of 10 cases from 1996 to 2005 and 81
cases from 2006 to 2019. Among the 10 patients who had an in
vitro susceptibility test from 1996 to 2005, four of them were sensitive to the antifungal drug voriconazole. Of the 81 patients who had
in vitro susceptibility test between 2006 and 2015, 41 were sensitive
to voriconazole, accounting for 37.3% of all patients (Table 4).
Among in vitro susceptibility test methods, the M27-A2, M27-A3
and E-test methods were used widely on T. asahii infection patients.

Fig. 3. Statistical analysis of drug susceptibility testing and clinical outcome. (a) In
vitro drug susceptibility testing of triazoles and amphotericin B. The P-value was calculated by using Fisher’s exact test. (b) Mortality rate of different infection types.

Drug selection
Regarding treatment and medication options for T. asahii infection, the ESCMID/ECMM guidelines recommended the use of
voriconazole for the treatment of trichosporosis in 2014. The
guidelines were based on the results of in vitro susceptibility testing, animal model testing and supporting evidence from a few
case reports of Trichosporon infection [49]. However, more
than 50 species of Trichosporon have been identified currently

and different species of Trichosporon exhibit different levels of
sensitivity to drugs. For example, the MIC of amphotericin B
for T. asahii, T. faecale and T. coremiiforme was relatively higher,
than that for T. inkin, T. ovoides, T. japonicum, T. domesticum, T.
montevideense and T. cutaneum [46, 53–55]. Therefore, this
guideline has a limited reference value for the usage of voriconazole in treatment of T. asahii infection.
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Fig. 4. Comparative analysis of 51 Chinese patients and 89 patients in other countries. Comparative distributions were shown for (a) infection types, (b) inducing
factors, (c) drug sensitivity and (d) mortality.

Of the 140 patients with T. asahii infections, the treatment
strategies were complex (Fig. 3a). The efficiency of single-drug
therapy of amphotericin B was 70.6%, whereas the efficiency of
triazole in antifungal therapy was 74.1%. The difference between
the two groups was statistically significant (P = 0.015). However,
the efficacy of a combined dosage of amphotericin B and triazole
was reduced to 57.9%. There was no significant difference
between the combination group and the single drug group (P >
0.05), but the efficacy of triazole in anti-T. asahii infection was
better than amphotericin B (P < 0.05).
Outcomes
Previous studies have shown that the mortality rate of
Trichosporon infection can range from 53% to 80% [48, 61, 63,
64], but these studies only examined the mortality rate, and did
not analyse the specific cause of death. They failed to answer questions such as whether the patient died from Trichosporon infection
or other underlying diseases or if the main cause of death was due
to complications resulting from the underlying disease. To clarify
the mortality rate due to T. asahii infection, we excluded patients
who died from underlying diseases and other causes of death.
Only patients with death caused by T. asahii infection were considered. Of the 140 patients with T. asahii infection, the overall mortality rate of 140 patients was 30.0%, and the mortality rate caused
by T. asahii infection was 13.6%. Furthermore, mortality was different in patients with varying infection types of T. asahii. Fungaemia
was associated with the highest mortality rate, 51.5%, including
30.3% caused by T. asahii infection. This was followed by

disseminated infection at 40.0%. Of note, 35% of deaths were
caused solely by T. asahii infection (Fig. 3b).
Comparative analysis of cases in China and other countries
Since there were a large number of patients reported in China, we
also statistically compared the characteristics of Chinese patients
with those of other countries. We found that fungaemia and pulmonary infection in Chinese patients was higher than in other countries
(>3-fold). On the other hand, the number of patients with urinary
tract infections in other countries was greater compared to China
(>3-fold) (Fig. 4a). For risk factors, we confirmed that antibiotic treatment and invasive medical device users were the most common in
both cohorts. However, the number of patients with risk factors
such as chemotherapy, neutrophil reduction and bacterial infection
was greater in other countries compared to China (>3-fold) (Fig. 4b).
For the methods of identification and diagnosis, both China
and other countries used standard morphological and biochemical methods (>50%). The results of the in vitro drug sensitivity
test were also very similar. Comparisons of clinical drug usage
showed no difference, and both groups preferred triazoles and
amphotericin B (Fig. 4c). However, the overall mortality rate
reported in Chinese patients was lower (21.6%) than that of
other countries (34.8%) (Fig. 4d).
Discussion
This study investigated 140 global T. asahii infection cases
reported within the past 23 years. For statistical and comparative
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analysis, we used critical criteria to select both English and
Chinese reports of T. asahii infections. We found that the number
of T. asahii infections showed a dramatic increase from 2006 to
2015 (107 cases) in Asia. We also found that the patients in
this study mainly used triazole antifungal drugs or amphotericin
B alone, or the combination of triazoles and amphotericin B. The
results showed that the antifungal effect of triazoles, such as voriconazole, fluconazole and itraconazole was the most effective in
the treatment of T. asahii infection. This is consistent with the
guidelines developed by ESCMID/ECMM in 2014. Furthermore,
we found that the combined usage of amphotericin B and triazole
was less effective than individual triazole drug usage. Therefore,
our results suggest that the first recommended drug for the treatment of T. asahii infection should be a triazole. The statistical
ranking of drug sensitivities based on in vitro susceptibility test
(Table 4) suggests that voriconazole would be the first choice
for treatment, followed by fluconazole, amphotericin B and
itraconazole.
Since many of T. asahii infections were reported in Chinese,
we further collected and investigated 51 Chinese cases. Through
the comparison of cases between China and other countries, we
found that although they are very similar for a majority of the criteria studied, there are still many differences. In particular, fungaemia and pulmonary infections were greater in Chinese
patients, but urinary tract infections had a lower frequency in
Chinese patients than in cases from other countries. Due to the
strict inclusion criteria in this study, the actual incidence of T.
asahii infections in the world is greater than 140 cases.
Therefore, a more accurate epidemiological analysis of T. asahii
infection requires collaboration with researchers from all over
the world. We found that many types of clinical information,
such as the infection process and the source of their pathogens,
are missing. But this information could be valuable for understanding the infection process and mechanism of T. asahii. For
example, a recent time series study of breakthrough IFIs [62]
defined different clinic trail patterns of breakthrough IFI. A similar analysis can be performed for T. asahii infections if detailed
and time series clinic records can be amassed. Meanwhile, acting
as a reference for the clinical drug selection to treat T. asahii
infection, our study can be improved by precisely controlling confounding factors including weight, vital organ function, etc. that
were inaccessible now. Therefore, specific information such as
the appropriate therapeutic dose, maintenance dose and duration
of treatment remain to be determined.
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Natural Science Foundation of China (Grant Numbers 81472892 and
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